

12TH MEETING OF THE EUROPEAN EGPA STUDY GROUP

25TH SEPTEMBER 2026 LONDON



KING'S VENUES AT LONDON BRIDGE

EESG MEETING PROGRAM

08.30 a.m. Welcome
D. Jackson, A. Nanzer

08.40 a.m. Lecture
The eosinophil – a historic perspective
A. Munitz (online)

► Session 1:

FROM MECHANISMS TO CLINICAL PRACTICE

Chairs: **A. Vaglio, R. Smith**

09.00 a.m. The epigenetics of EGPA: a case-control methylome-wide association study
A. Peired

09.10 a.m. Familial EGPA study
D. Martorana, C. Rella

09.20 a.m. Overall long-term follow-up and damage accrual in EGPA across Europe
A. Mohammad, R. Padoan

09.30 a.m. A European study on eosinophil-associated diseases: the Cohesion project
G. Lefevre (online)

09.40 a.m. Cardiac EGPA
T. Ismail

09.50 a.m. Upper & lower airways eosinophilic involvement in EGPA patients under targeted treatment
M. Caminati

10.00 a.m. Developing diagnostic criteria for EGPA
V. Cottin

10.10 a.m. Update of the EGPA Recommendations
G. Emmi, A. Vaglio

10.20 a.m. **Open discussion**

10.40 a.m. Coffee Break

► Session 2:

OBSERVATIONAL AND CLINICAL STUDIES

Chairs: **A. Nanzer, M. Fernando**

11.10 a.m. FeNO - a useful biomarker in EGPA. Proposal of two studies
F. Cefaloni, P. Cameli

11.20 a.m. Comparison of Mepolizumab plus Rituximab and/or Cyclophosphamide vs Rituximab and/or Cyclophosphamide alone for the induction of remission of life-threatening relapsing EGPA patients
M. Fornaro

11.30 a.m. Long term efficacy, super responders and safety of mepolizumab in EGPA
A. Bettiol

11.40 a.m. First line treatment of MEPO and switching the dose of mepolizumab in EGPA
I. Mattioli

11.50 a.m. IL-5 Pathway inhibitors during pregnancy in eosinophilic disorders: results of a retrospective multicenter study
G. Pacini

12.00 p.m. Effectiveness and Safety of Benralizumab 30mg/month in the European Real-Life Setting: the BELONG Study
F. Fagni

12.10 p.m. Explore the Efficacy and Mechanism of Action of Tezepelumab in Eosinophilic Granulomatosis With Polyangiitis (RACEMATE)
S. Siddiqui

12.20 p.m. Insights into the molecular basis of EGPA
M. Villa

12.30 p.m. **Open discussion**

12.50 p.m. Lunch and group photo

02.00 p.m. Lecture
Nasal polyps in EGPA: scalpel or biologic?
F. Pirola

► **Session 3:**

ONGOING AND COMPLETED STUDIES

Chairs: **A. Egan, D. Jackson**

02.20 p.m. A European EGPA patients' association survey
F. Torracca, E. Durante, K. Misztal

02.30 p.m. Development of a new disease activity score for EGPA
A. Bettiol

02.40 p.m. The effectiveness and safety of mepolizumab 300 mg/month in newly diagnosed EGPA patients: the MEPEARL study
R. Padoan

02.50 p.m. Gastrointestinal involvement in HES and EGPA treated with Mepolizumab
A. Gatti

03.00 p.m. Tezepelumab monotherapy in EGPA
A. Nanzer

03.10 p.m. EESG biobank initiative
G. Emmi, A. Vaglio

03.20 p.m. **Open discussion**

03.40 p.m. Coffee break

03.55 p.m. Lecture
EGPA relapse pathogenesis – what have we learned from severe asthma studies?
D. Jackson

► **Session 4:**

ONGOING AND FUTURE STUDIES

Chairs: **F. Roufosse, G. Emmi**

04.15 p.m. Influence of treatment on systemic relapses in EGPA patients: a multicentre retrospective study
M. Piga, F. Roufosse

04.25 p.m. Tailoring biological maintenance therapy in severe EGPA: rituximab, mepolizumab, or both?
P. Delvino

04.35 p.m. Biomarkers in EGPA
L. Moroni

04.45 p.m. Changes in mortality in EGPA following the Introduction of Anti-IL5 Therapy: an EESG and FAIRVASC study
A. Bettiol

04.55 p.m. Phenotyping and predictors of treatment response in HES and ANCA-negative EGPA: a multicenter study
J. Mora

05.05 p.m. Distinguishing pulmonary phenotypes in EGPA: a CT-based comparison of lung-limited and systemic disease
F. Ferro (online)

05.10 p.m. **Open discussion**

05.25 p.m. **2027 EESG Meeting Save the Date and Venue**

05.30 p.m. Closing
G. Emmi, A. Vaglio, D. Jackson, A. Nanzer

MEETING ORGANIZERS

David Jackson
Alexandra Nanzer

EESG COORDINATORS

Giacomo Emmi
Benjamin Terrier
Augusto Vaglio

GENERAL INFORMATION

Meeting Venue

KING'S VENUES AT LONDON BRIDGE
(formerly Science Gallery London)

Great Maze Pond
London SE1 9GU

FACULTY

Alessandra Bettiol, Italy
Paolo Cameli, Italy
Marco Caminati, Italy
Francesca Cefaloni, UK
Vincent Cottin, France
Paolo Delvino, Italy
Eugenia Durante, Italy
Allyson Egan, Ireland
Giacomo Emmi, Switzerland
Filippo Fagni, Germany
Michelle Fernando, UK
Francesco Ferro, Italy
Marco Fornaro, Italy
Alessia Gatti, Italy
Tevfik Ismail, UK
David Jackson, UK
Guillaume Lefevre, France
Davide Martorana, Italy
Irene Mattioli, Italy

Kinga Misztal, Poland
Aladdin Mohammad, Sweden
Jacopo Mora, Italy
Luca Moroni, Italy
Ariel Munitz, Israel
Alexandra Nanzer, UK
Greta Pacini, Italy
Roberto Padoan, Italy
Anna Peired, Italy
Mario Piga, Italy
Francesca Pirola, UK
Carlotta Rella, Italy
Florence Roufosse, Belgium
Salman Siddiqui, UK
Rona Smith, UK
Francesca Torracca, Italy
Augusto Vaglio, Italy
Matteo Villa, Austria

ORGANIZING SECRETARIAT



Viale dei Mille 137 – 50131 Firenze (FI)
Tel. +39 055 0671000
E.mail: marta.bartoletti@eve-lab.it

The background of the entire image is a faded, light-colored photograph of the Tower Bridge in London. The bridge's two massive stone towers are prominent, with their intricate Gothic-style architecture and multiple spires. The bridge's suspension cables and walkways are visible, extending from the towers. The sky is a pale, clear blue, and some city buildings are visible in the distance behind the bridge.

<https://eestudygroup.com/>

Follow us on 